Claudio Laudani/X
Nov 18, 2025, 15:08
Claudio Laudani: DOACs Have Transformed the Landscape of Anticoagulation
Claudio Laudani, Cardiovascular Disease Fellow UNICT, Post-Doc Research Scholar UFHealth JAX, shared on LinkedIn:
”Direct oral anticoagulants (DOACs) have transformed the landscape of anticoagulation, offering more predictable pharmacology, improved safety, and easier management compared to vitamin K antagonists.
In this comprehensive review, we examine:
- Pharmacokinetic and pharmacodynamic profiles of apixaban, rivaroxaban, dabigatran, and edoxaban.
- Evidence supporting their use across atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and atherosclerosis compared with other antithrombotic strategies.
- How to optimize DOAC therapy in vulnerable scenarios (renal impairment, elderly patients, perioperative management).
- Remaining gaps and unmet clinical needs where further research is required, such as patients with rheumatic heart disease, mechanical heart valves, antiphospholipid syndrome, and patients with LVAD.”
Read the full article here.
Article: Safety and optimal use of direct oral anticoagulant therapy
Authors: Claudio Laudani, Luis Ortega-Paz, Ali Zgheib, Georges El Khoury, Mohmmad Alawajneh, Maryam Farahmandsadr, Davide Capodanno, Dominick J Angiolillo

Stay updated on all scientific advances in the field of thrombosis with Hemostasis Today.
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week
-
Nov 8, 2026, 14:55Andra T.: Antiphospholipid Syndrome and Its Thrombotic Risks
-
Nov 8, 2026, 14:06Shayan Mohammadmoradi: ZEUS Trial-Inflammation Reduction Without Fewer Cardiovascular Events